personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Intravitreal sodium chloride 5% as a new treatment for diabetic macular edema

Session Details

Session Title: Quick Fire Free Paper Session 04

Session Date/Time: Sunday 29/09/2013 | 11:00-13:00

Paper Time: 12:05

Venue: Hall C (Level 1)

First Author: A.Elhabbak EGYPT

Co Author(s):    A. Abd El Alim Mohamed   M. Abdrabbo   H. El Shewy        

Abstract Details

"Purpose:

To evaluate the safety and efficacy of intravitreal Hypertonic Solution (Sodium Chloride (Na Cl 5%) in the treatment of Diabetic Macular Edema (DME).

Setting:

Dar El-Eyoun Hospital Egyptian Eye Academy

Methods:

Twenty-four eyes of 24 diabetic patients with DME. Using 0.1ml of sodium chloride 5% as a single intravitreal injection in DME under complete aseptic condition. Patients were followed up for 6 months. Best-corrected visual acuity (BCVA), and changes in optical coherence tomography (OCT) were assessed. Main Outcome Measures Changes in BCVA, decrease in the central foveal thickness (CFT) by OCT, and any significant local or systemic complication during the 6-month follow-up period.

Results:

Fifteen (62.5%) eyes had an improved BCVA of 2 or more lines at 6 months. The improvement at 1 and 6 month compared with baseline BCVA was 1.6 and 2.5 lines, respectively. The OCT results showed significant improvement of the average CFT from 340 to 260 micron, after a single injection in 14 eyes at 3 months, and in…at 6 months. No ocular or systemic complications were noted during the follow-up period.

Conclusions:

The intravitreal injection of NaCl 5% solution appears to be a new promising line of treatment for diabetic macular edema, resulting in both functional and anatomic improvements. Further studies are necessary to evaluate the optimal dose, concentration, number of injections, and safety of this procedure."

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy